|
Biolinerx Ltd. (Blrx) DCF -Bewertung |
Fully Editable: Tailor To Your Needs In Excel Or Sheets
Professional Design: Trusted, Industry-Standard Templates
Investor-Approved Valuation Models
MAC/PC Compatible, Fully Unlocked
No Expertise Is Needed; Easy To Follow
BioLineRx Ltd. (BLRX) Bundle
Erhöhen Sie die Effizienz und verbessern Sie die Präzision mit unserem (Blrx) DCF -Taschenrechner! In diesem Tool können Sie mit den Daten und anpassbaren Annahmen von Biolinerx Ltd. und anpassbaren Annahmen wie ein erfahrener Investor die Vorhersage, Analyse und Value Biolinerx Ltd. ermöglichen.
Discounted Cash Flow (DCF) - (USD MM)
| Year | AY1 2020 |
AY2 2021 |
AY3 2022 |
AY4 2023 |
AY5 2024 |
FY1 2025 |
FY2 2026 |
FY3 2027 |
FY4 2028 |
FY5 2029 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | .0 | .0 | .0 | 4.8 | 28.9 | 36.2 | 45.2 | 56.5 | 70.7 | 88.3 |
| Revenue Growth, % | 0 | 0 | 0 | 0 | 502.92 | 25 | 25 | 25 | 25 | 25 |
| EBITDA | -22.0 | -25.3 | -28.5 | -57.1 | 3.9 | 15.4 | 19.3 | 24.1 | 30.2 | 37.7 |
| EBITDA, % | 100 | 100 | 100 | -1188.77 | 13.54 | 42.71 | 42.71 | 42.71 | 42.71 | 42.71 |
| Depreciation | .9 | .7 | .7 | 1.4 | 4.1 | 24.8 | 31.0 | 38.8 | 48.5 | 60.6 |
| Depreciation, % | 100 | 100 | 100 | 28.83 | 14.05 | 68.58 | 68.58 | 68.58 | 68.58 | 68.58 |
| EBIT | -22.9 | -26.0 | -29.2 | -58.4 | -.1 | 14.4 | 18.0 | 22.6 | 28.2 | 35.2 |
| EBIT, % | 100 | 100 | 100 | -1217.6 | -0.50795 | 39.9 | 39.9 | 39.9 | 39.9 | 39.9 |
| Total Cash | 22.6 | 57.1 | 51.1 | 43.0 | 19.6 | 33.8 | 42.3 | 52.9 | 66.1 | 82.6 |
| Total Cash, percent | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 |
| Account Receivables | .1 | .1 | .7 | .7 | 3.9 | 23.7 | 29.7 | 37.1 | 46.4 | 58.0 |
| Account Receivables, % | 100 | 100 | 100 | 14.75 | 13.35 | 65.62 | 65.62 | 65.62 | 65.62 | 65.62 |
| Inventories | .0 | .0 | -41.2 | 2.0 | 3.1 | 25.4 | 31.8 | 39.7 | 49.7 | 62.1 |
| Inventories, % | 100 | 100 | 100 | 40.69 | 10.87 | 70.31 | 70.31 | 70.31 | 70.31 | 70.31 |
| Accounts Payable | 5.9 | 5.6 | 7.0 | 10.9 | 5.6 | 30.3 | 37.9 | 47.4 | 59.2 | 74.1 |
| Accounts Payable, % | 100 | 100 | 100 | 226.44 | 19.29 | 83.86 | 83.86 | 83.86 | 83.86 | 83.86 |
| Capital Expenditure | .0 | -.1 | -.3 | -.3 | -.1 | -.5 | -.6 | -.7 | -.9 | -1.1 |
| Capital Expenditure, % | 100 | 100 | 100 | -6.19 | -0.18659 | -1.27 | -1.27 | -1.27 | -1.27 | -1.27 |
| Tax Rate, % | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| EBITAT | -23.6 | -27.1 | -22.1 | -58.4 | -.1 | 13.7 | 17.2 | 21.5 | 26.8 | 33.5 |
| Depreciation | ||||||||||
| Changes in Account Receivables | ||||||||||
| Changes in Inventories | ||||||||||
| Changes in Accounts Payable | ||||||||||
| Capital Expenditure | ||||||||||
| UFCF | -16.9 | -26.8 | 20.3 | -96.6 | -5.8 | 20.7 | 42.9 | 53.6 | 67.0 | 83.8 |
| WACC, % | 46.5 | 46.5 | 35.73 | 46.5 | 46.5 | 44.35 | 44.35 | 44.35 | 44.35 | 44.35 |
| PV UFCF | ||||||||||
| SUM PV UFCF | 81.5 | |||||||||
| Long Term Growth Rate, % | 2.00 | |||||||||
| Free cash flow (T + 1) | 85 | |||||||||
| Terminal Value | 202 | |||||||||
| Present Terminal Value | 32 | |||||||||
| Enterprise Value | 114 | |||||||||
| Net Debt | 5 | |||||||||
| Equity Value | 109 | |||||||||
| Diluted Shares Outstanding, MM | 2 | |||||||||
| Equity Value Per Share | 54.64 |
What You Will Receive
- Comprehensive Financial Model: BioLineRx Ltd.’s actual data facilitates accurate DCF valuation.
- Complete Forecast Flexibility: Modify revenue growth, profit margins, WACC, and other essential factors.
- Real-Time Calculations: Automated updates allow you to view results immediately as you adjust parameters.
- Professional-Grade Template: A polished Excel file crafted for high-quality valuation presentations.
- Adaptable and Reusable: Designed for versatility, enabling repeated application for in-depth forecasts.
Key Features
- Comprehensive Data: BioLineRx Ltd.'s historical financial statements and pre-filled projections.
- Customizable Parameters: Adjust WACC, tax rates, revenue growth, and EBITDA margins as needed.
- Real-Time Insights: Monitor BioLineRx Ltd.'s intrinsic value recalculating instantly.
- Intuitive Visualizations: Dashboard graphs illustrate valuation results and essential metrics.
- Designed for Precision: A professional-grade tool for analysts, investors, and finance professionals.
How It Works
- 1. Access the Template: Download and open the Excel file containing BioLineRx Ltd.'s preloaded data.
- 2. Modify Assumptions: Adjust critical inputs such as growth rates, WACC, and capital expenditures.
- 3. View Results in Real-Time: The DCF model automatically computes intrinsic value and NPV.
- 4. Explore Scenarios: Analyze various forecasts to evaluate different valuation results.
- 5. Utilize with Assurance: Present expert valuation insights to back your strategic decisions.
Why Choose This Calculator for BioLineRx Ltd. (BLRX)?
- User-Friendly Interface: Perfect for both novices and seasoned professionals.
- Customizable Inputs: Adjust parameters easily to suit your financial analysis.
- Real-Time Valuation: Observe immediate updates to BioLineRx’s valuation as you modify inputs.
- Pre-Loaded Data: Comes with BioLineRx’s actual financial information for swift evaluations.
- Preferred by Experts: Utilized by investors and analysts for making well-informed choices.
Who Should Use This Product?
- Individual Investors: Make informed decisions about buying or selling BioLineRx Ltd. (BLRX) stock.
- Financial Analysts: Streamline valuation processes with ready-to-use financial models specific to BioLineRx Ltd. (BLRX).
- Consultants: Deliver professional valuation insights regarding BioLineRx Ltd. (BLRX) to clients quickly and accurately.
- Business Owners: Understand how biotech companies like BioLineRx Ltd. (BLRX) are valued to guide your own strategy.
- Finance Students: Learn valuation techniques using real-world data and scenarios related to BioLineRx Ltd. (BLRX).
What the Template Contains
- Comprehensive DCF Model: Editable template featuring detailed valuation calculations.
- Real-World Data: BioLineRx Ltd.'s (BLRX) historical and projected financials preloaded for analysis.
- Customizable Parameters: Modify WACC, growth rates, and tax assumptions to explore various scenarios.
- Financial Statements: Complete annual and quarterly breakdowns for enhanced insights.
- Key Ratios: Integrated analysis for profitability, efficiency, and leverage metrics.
- Dashboard with Visual Outputs: Charts and tables designed for clear, actionable results.
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.